[{"orgOrder":0,"company":"Sanford Burnham Prebys Medical Discovery Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scientists Identify a New Drug Target for Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Vitronectin","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Sanford Burnham Prebys Medical Discovery Institute","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sanford Burnham Prebys Medical Discovery Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sanford Bu.."},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Astellas, University of Pittsburgh Enter Research Collaboration for Dry Age-Related Macular Degeneration Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"September 2020","year":"2020","type":"Collaboration","leadProduct":"AAV-based gene therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"The University of Pittsburgh School of Medicine \/ Astellas Pharma","highestDevelopmentStatusID":"2","companyTruncated":"The Univer.."},{"orgOrder":0,"company":"Synedgen","sponsor":"National Eye Institute","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Synedgen Receives Supplemental NEI Funding To Identify Lead Development Candidate for Ocular Mustard Gas Injury Program","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Synedgen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Synedgen \/ National Eye Institute","highestDevelopmentStatusID":"2","companyTruncated":"Synedgen \/.."},{"orgOrder":0,"company":"SemaThera Inc","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"March 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Semaphorin-3A","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SemaThera Inc","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"SemaThera Inc \/ Roche","highestDevelopmentStatusID":"2","companyTruncated":"SemaThera .."},{"orgOrder":0,"company":"Mosaic Biosciences","sponsor":"Ocular Therapeutix","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ocular Therapeutix\u2122 and Mosaic Biosciences Ink Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Complement","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Mosaic Biosciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Mosaic Biosciences \/ Ocular Therapeutix","highestDevelopmentStatusID":"2","companyTruncated":"Mosaic Bio.."},{"orgOrder":0,"company":"Intergalactic Therapeutics","sponsor":"ATPGroup","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"ATP Unveils Non-Viral Gene Therapy Innovator Intergalactic Therapeutics with $75 Million in Series A Funding","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Series A Financing","leadProduct":"Non-viral Based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intergalactic Therapeutics","amount2":0.080000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.080000000000000002,"dosageForm":"","sponsorNew":"Intergalactic Therapeutics \/ ATP","highestDevelopmentStatusID":"2","companyTruncated":"Intergalac.."},{"orgOrder":0,"company":"Intellia Therapeutics","sponsor":"SparingVision","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR\/Cas9 Technology","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Collaboration","leadProduct":"SPVN50","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Intellia Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Intellia Therapeutics \/ SparingVision","highestDevelopmentStatusID":"2","companyTruncated":"Intellia T.."},{"orgOrder":0,"company":"Kriya Therapeutics","sponsor":"Patient Square Capital","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kriya Announces $270 Million Series C Financing to Advance Fully Integrated Gene Therapy Engine","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2022","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Kriya Therapeutics","amount2":0.27000000000000002,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.27000000000000002,"dosageForm":"","sponsorNew":"Kriya Therapeutics \/ Patient Square Capital","highestDevelopmentStatusID":"2","companyTruncated":"Kriya Ther.."},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"engEx-AAV","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codiak Bio.."},{"orgOrder":0,"company":"Toolgen","sponsor":"mCureX","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OliX Pharmaceuticals Subsidiary mCureX Announces mRNA Technology Collaboration with ToolGen for Rare Eye Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2022","year":"2022","type":"Collaboration","leadProduct":"TGT-101","moa":"VEGF","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Toolgen","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Toolgen \/ mCureX","highestDevelopmentStatusID":"2","companyTruncated":"Toolgen \/ .."},{"orgOrder":0,"company":"VivaVision","sponsor":"Everads Therapy","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VivaVision and Everads Collaborate to Develop Durable and Effective Therapies for Retinal Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"VivaVision","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"VivaVision \/ Everads Therapy","highestDevelopmentStatusID":"2","companyTruncated":"VivaVision.."},{"orgOrder":0,"company":"Avista Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"$1,007.5 million","upfrontCash":"$7.5 million","newsHeadline":"Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Partnership","leadProduct":"AAV-based Gene Therapy","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Avista Therapeutics","amount2":1.01,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":1.01,"dosageForm":"","sponsorNew":"Avista Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"2","companyTruncated":"Avista The.."},{"orgOrder":0,"company":"Capsida","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","amount":"$665.0 million","upfrontCash":"$70.0 million","newsHeadline":"AbbVie and Capsida Biotherapeutics Expand Strategic Collaboration to Develop Targeted Genetic Medicines for Eye Diseases with High Unmet Need","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Capsida","amount2":0.67000000000000004,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.67000000000000004,"dosageForm":"","sponsorNew":"Capsida \/ AbbVie","highestDevelopmentStatusID":"2","companyTruncated":"Capsida \/ .."},{"orgOrder":0,"company":"SpliceBio","sponsor":"Spark Therapeutics, Inc","pharmaFlowCategory":"D","amount":"$216.0 million","upfrontCash":"Undisclosed","newsHeadline":"SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2023","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"SpliceBio","amount2":0.22,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.22,"dosageForm":"","sponsorNew":"SpliceBio \/ Spark Therapeutics, Inc","highestDevelopmentStatusID":"2","companyTruncated":"SpliceBio .."},{"orgOrder":0,"company":"Ray Therapeutics","sponsor":"CIRM","pharmaFlowCategory":"D","amount":"$4.0 million","upfrontCash":"Undisclosed","newsHeadline":"Ray Therapeutics Receives $4M in Funding from The California Institute for Regenerative Medicine (CIRM)","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Discovery","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2023","year":"2023","type":"Funding","leadProduct":"RTx-021","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Discovery","graph3":"Ray Therapeutics","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Discovery","highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Ray Therapeutics \/ CIRM","highestDevelopmentStatusID":"2","companyTruncated":"Ray Therap.."}]